Added to YB: 2025-11-06
Pitch date: 2025-10-31
NVCT [bullish]
Nuvectis Pharma, Inc.
+13.11%
current return
Author Info
No bio for this author
Company Info
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Market Cap
$154.2M
Pitch Price
$6.71
Price Target
40.00 (+427%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-4.43
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Notes on $NVCT
NVCT: SRC/YES1 TKI targeting NSCLC with 4x larger TAM than NUVL's ALK program. Phase 1b starting mid-2025 with 90-95% target inhibition at 200mg, favorable safety vs dasatinib. $40 price target on NUVL comp ($5B valuation vs NVCT's $200M). Combo potential with Tagrisso for $2B+ resistance market.
Read full article (19 min)